File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Alternative use of isoflurane and propofol confers superior cardioprotection than using one of them alone in a dog model of cardiopulmonary bypass

TitleAlternative use of isoflurane and propofol confers superior cardioprotection than using one of them alone in a dog model of cardiopulmonary bypass
Authors
KeywordsCardiopulmonary Bypass
Ischemia/Reperfusion Injury
Isoflurane
Oxidative Stress
Propofol
Issue Date2012
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejphar
Citation
European Journal Of Pharmacology, 2012, v. 677 n. 1-3, p. 138-146 How to Cite?
AbstractOur previous clinical study reported that isoflurane preconditioning and high-dose propofol posttreatment attenuated myocardial ischemia/reperfusion injury of patients in surgery with cardiopulmonary bypass (CPB). This study was designed to confirm this cardiac protection by use of a dog CPB model and to elucidate the related mechanism. Adult mongrel male dogs undergoing standard CPB were assigned into 4 groups: Sham group, Propofol group, Isoflurane (Iso) group and isoflurane in combination of propofol (pre-Iso + P) group. After induction, anesthesia was maintained with propofol (Propofol group), isoflurane (Iso group) or isoflurane preconditioning in combination with propofol posttreatment (pre-Iso + P group). After 2 h cardiac arrest and CPB, aortic cross-clamping was released to allow 2 h reperfusion. The results demonstrated that joint use of isoflurane and propofol facilitated cardiac functional recovery, improved myocardial oxygen utilization and decreased cardiac enzyme release. Also, the oxidative damage caused by ischemia/reperfusion injury was remarkably attenuated. Linear regression analysis showed that cardiac function performance and oxidative stress status were inversely correlated, indicating the improved cardiac function was in closed association with the attenuation of oxidative stress. In addition, the cardiac oxygen consumption (VO 2) was found to be significantly associated with the above cardiac function and oxidative stress parameters, suggesting VO 2 was predictive for the levels of cardiac damage and oxidative stress. Therefore, we conclude that alternative use of isoflurane and propofol confers superior cardioprotection against postischemic myocardial injury and dysfunction, and this protection was probably mediated by attenuation of cardiac oxidative damage. © 2011 Elsevier B.V. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/147288
ISSN
2014 Impact Factor: 2.532
2014 SCImago Journal Rankings: 0.871
ISI Accession Number ID
Funding AgencyGrant Number
National Nature Science Foundation of China81100180
30801083
81070117
China Postdoctoral Specialized Science Foundation201003700
Specialized Research Fund for the Doctoral Program of Higher Education20100181120090
Major Program of the Clinical High and New Technology of PLA2010gxjs039
Society of Cardiovascular Anesthesiologists (SCA)
Funding Information:

This study was supported by grants from the National Nature Science Foundation of China (81100180, 30801083 and 81070117), the China Postdoctoral Specialized Science Foundation (201003700), the Specialized Research Fund for the Doctoral Program of Higher Education (20100181120090), the Major Program of the Clinical High and New Technology of PLA (2010gxjs039) and The Society of Cardiovascular Anesthesiologists (SCA) research starter grant (2008 to Dr Xia).

References

 

DC FieldValueLanguage
dc.contributor.authorLi, Ten_US
dc.contributor.authorWu, Wen_US
dc.contributor.authorYou, Zen_US
dc.contributor.authorZhou, Ren_US
dc.contributor.authorLi, Qen_US
dc.contributor.authorZhu, Den_US
dc.contributor.authorLi, Hen_US
dc.contributor.authorXiang, Xen_US
dc.contributor.authorIrwin, MGen_US
dc.contributor.authorXia, Zen_US
dc.contributor.authorLiu, Jen_US
dc.date.accessioned2012-05-29T06:01:16Z-
dc.date.available2012-05-29T06:01:16Z-
dc.date.issued2012en_US
dc.identifier.citationEuropean Journal Of Pharmacology, 2012, v. 677 n. 1-3, p. 138-146en_US
dc.identifier.issn0014-2999en_US
dc.identifier.urihttp://hdl.handle.net/10722/147288-
dc.description.abstractOur previous clinical study reported that isoflurane preconditioning and high-dose propofol posttreatment attenuated myocardial ischemia/reperfusion injury of patients in surgery with cardiopulmonary bypass (CPB). This study was designed to confirm this cardiac protection by use of a dog CPB model and to elucidate the related mechanism. Adult mongrel male dogs undergoing standard CPB were assigned into 4 groups: Sham group, Propofol group, Isoflurane (Iso) group and isoflurane in combination of propofol (pre-Iso + P) group. After induction, anesthesia was maintained with propofol (Propofol group), isoflurane (Iso group) or isoflurane preconditioning in combination with propofol posttreatment (pre-Iso + P group). After 2 h cardiac arrest and CPB, aortic cross-clamping was released to allow 2 h reperfusion. The results demonstrated that joint use of isoflurane and propofol facilitated cardiac functional recovery, improved myocardial oxygen utilization and decreased cardiac enzyme release. Also, the oxidative damage caused by ischemia/reperfusion injury was remarkably attenuated. Linear regression analysis showed that cardiac function performance and oxidative stress status were inversely correlated, indicating the improved cardiac function was in closed association with the attenuation of oxidative stress. In addition, the cardiac oxygen consumption (VO 2) was found to be significantly associated with the above cardiac function and oxidative stress parameters, suggesting VO 2 was predictive for the levels of cardiac damage and oxidative stress. Therefore, we conclude that alternative use of isoflurane and propofol confers superior cardioprotection against postischemic myocardial injury and dysfunction, and this protection was probably mediated by attenuation of cardiac oxidative damage. © 2011 Elsevier B.V. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejpharen_US
dc.relation.ispartofEuropean Journal of Pharmacologyen_US
dc.subjectCardiopulmonary Bypassen_US
dc.subjectIschemia/Reperfusion Injuryen_US
dc.subjectIsofluraneen_US
dc.subjectOxidative Stressen_US
dc.subjectPropofolen_US
dc.titleAlternative use of isoflurane and propofol confers superior cardioprotection than using one of them alone in a dog model of cardiopulmonary bypassen_US
dc.typeArticleen_US
dc.identifier.emailXia, Z:zyxia@hkucc.hku.hken_US
dc.identifier.authorityXia, Z=rp00532en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.ejphar.2011.12.030en_US
dc.identifier.pmid22222823-
dc.identifier.scopuseid_2-s2.0-84856284379en_US
dc.identifier.hkuros203045-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84856284379&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume677en_US
dc.identifier.issue1-3en_US
dc.identifier.spage138en_US
dc.identifier.epage146en_US
dc.identifier.isiWOS:000300731200020-
dc.publisher.placeNetherlandsen_US
dc.identifier.citeulike10190168-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats